Thermo Fisher Scientific announced it is expanding its footprint in the European Union and investing $35 million in a state-of-the-art pharma services supply chain facility in Rheinfelden (Baden) Germany.
Company representatives joined Mayor Eberhardt at the Rheinfelden council meeting to unveil the details of the project. The new facility will leverage the latest technology and modern infrastructure to significantly increase European capacity for cold and ambient clinical trial materials in support of complex clinical research and so meet the growing needs of customers. The facility will be scalable for mixed-use space and provide a strategic logistical location for shipping either by road or air.
The company expects to start construction in Q4′ 2018 for the 8,000 square meter facility at the 26,000 square meter site with an anticipated completion within 12 to 18 months. Once complete, this new facility will provide up to 200 new jobs locally. The investment includes the option for additional expansion with the potential for doubling the footprint.
The company’s decision to expand is in response to a growing demand for global clinical supply services, worldwide. The new facility will also serve to address GDP guidelines, Clinical Trial Regulations Annex 6 and the new Falsified Medicines Directive 2019. This GMP/GDP facility builds on the company’s existing footprint of 20 purpose-built cGMP facilities globally.
Thermo Fisher’s Pharma Services develops unique solutions and business models to help customers manage the clinical development process and provides flexible manufacturing options to address client needs in an evolving marketplace.